艾司西酞普兰与度洛西汀对抑郁症患者述情障碍疗效的对比研究-东南大学学报医学版

艾司西酞普兰与度洛西汀对抑郁症患者述情障碍疗效的对比研究

单位：1. 东南大学附属中大医院心理精神科, 江苏南京 210009;
2. 中国人民解放军94654部队卫生队, 江苏南京 210046

分类号：R749.4

出版年·卷·期（页码）：2015·34·第六期（971-975）

摘要：

目的:探讨艾司西酞普兰和度洛西汀对抑郁症患者述情障碍的疗效.方法:对艾司西酞普兰组29例患者和度洛西汀组24例患者分别在基线、服药2周及8周进行TAS-20及HAMD-17测试.结果:两组抑郁症患者TAS-20总分、因子1分数、因子2分数在服药2、8周均逐渐降低,差异具有统计学意义(P<0.05或0.01);TAS-20总分2周减分值度洛西汀组高于艾司西酞普兰组(P<0.05);TAS-20总分、因子1的8周减分值度洛西汀组高于艾司西酞普兰组(P<0.05或0.01).治疗前抑郁症患者文化程度与因子3分数、TAS总分呈负相关, 治疗8周后HAMD-17总分与因子1分数、TAS总分呈显著正相关,发病次数及年龄与因子3分数呈显著正相关,文化程度与因子3分数呈负相关.结论:艾司西酞普兰及度洛西汀均有改善抑郁症患者述情障碍之效,其中度洛西汀的效果更为明显.

Objective: To compare the efficacy on alexithymia between escitalopram and duloxetine in patients with major depressive disorder (MDD). Methods: This study included 53 MDD patients who were treated with two different treatments: escitalopram (n=29 subjects) or duloxetine (n=24 subjects). Psychopathological assessment was performed at baseline, the end of 2 weeks and after 8 weeks of treatment with the 20-item Toronto Alexithymia Scale (TAS-20) for alexithymia, and the 17-item Hamilton Depression Scale (HAMD-17) for depression respectively. Results: In the inter-group comparison, two groups respectively showed significant reductions at the end of 2nd and 8th week for total score, factor 1 and factor 2 of TAS-20 compared to those at the baseline (P<0.05 or P<0.01). In the between-group comparison, duloxetine group showed higher reduction than escitalopram group for total score of TAS-20 at the end of 2nd week, and both total score and factor 1 were significantly lower in duloxetine group than in escitalopram one at the end of 8th week. Education years were negatively related to factor 3 and TAS total score before treatment. After 8 weeks treatment, HAMD-17 score was positively correlated with factor 1 and TAS total score,admission times and age were positively correlated with factor 3, we also found education years were negatively related to factor 3 after treatment. Conclusion: Both duloxetine and escitalopram could alleviate alexithymia in MDD, and duloxetine showed better efficacy on alexithymia than escitalopram.

参考文献：

[1] NIERENBERG A A,GREIS J H,MALLINEKRNDT C H,et al.Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder:onset of antidepressant action:a non-inferiority study[J].Curr Med Res Opin,2007,23(2):401-416.
[2] 徐扬.度洛西汀与艾司西酞普兰治疗抑郁症的临床疗效研究[J].中国民康医学,2013,25(11):49-50.
[3] TAYLOR G J,BAGBY R M,PARKER J D A.Disorder of affect regulation:alexithymia in medical and psychiatric illness[M].Cambridge:Cambridge University Press,1997.
[4] TAYLOR G J.Recent developments in alexithymia theory and research[J].Can J Psychiatry,2000,45(2):134-142.
[5] 杨程甲,许明智,贾福军,等.抑郁症患者述情障碍及其特征[J].广东医学,2010, 31(16):2072-2074.
[6] LI S, ZHANG B, GUO Y.The association between alexithymia as assessed by the 20-item Toronto Alexithymia Scale and depression:a meta-analysis[J].Psychiatry Res, 2015, 227(1):1-9.
[7] 张作记.行为医学量表手册[J].中国行为医学科学,2001,10(特刊):225-227.
[8] 蚁金瑶,姚树桥,朱熊兆.TAS-20中文版的信度、效度分析[J].中国心理卫生杂志,2003, 17(11):763-767.
[9] HINTIKKA J, HONKALAMPI K, LEHTONEN J,et al.Are alexithymia and depression distinct or overlapping constructs? A study in a general population[J].Compr Psychiatry,2001,42(3):234-239.
[10] SAARIJARVI S,SALMINEN J K,TOIKKA T B.Alexithymia and depression.A 1-year follow-up study in outpatients with major depression[J].J Psychosom Res, 2001,51(6):729-733.
[11] 周丽.述情障碍的神经机制[J].神经病与精神卫生,2007,7(1):61-62.
[12] WIEBKING C,NORTHOFF G.Neural activity during interoceptive awareness and its associations with alexithymia—An fMRI study in major depressive disorder and non-psychiatric controls[J].Front Psychol,2015,6:589.
[13] 苏巧荣,苏林雁.抑郁症患者的述情障碍[J].中国临床康复,2005,9(8):10-11.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录